Armistice Capital’s Mangoceuticals MGRX Stock Holding History

Armistice Capital’s Portfolio MGRX Stock Details MGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,536,000	Closed	-$1.14M	–	392
2025 Q4	$1.14M	Buy	+1,536,000	New	+$2.49M	0.01%	172

Other funds holding MGRX

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ACA

Ackerman Capital Advisors Dallas, Texas $488M AUM 14.36% 1-Year Est. Return

StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return

Armistice Capital's MGRX Position: Q1 2026 in Review

Armistice Capital sold out of Mangoceuticals (MGRX) in Q1 2026, closing a stake of 1,536,000 shares — an estimated $1.14M sold.

Armistice Capital first reported a position in MGRX in Q4 2025 and held it in 1 quarter. The position peaked at $1.14M in Q4 2025. 18 funds tracked by Wall St. Rank hold MGRX as of Q1 2026.

Armistice Capital reported no remaining Mangoceuticals position as of Q1 2026 after selling out during the quarter.
Armistice Capital sold 1,536,000 Mangoceuticals shares in Q1 2026, an estimated $1.14M.
Armistice Capital first reported a position in Mangoceuticals in Q4 2025 and held it in 1 quarter.
Armistice Capital's Mangoceuticals position peaked at $1.14M in Q4 2025.
18 funds tracked by Wall St. Rank held Mangoceuticals as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.